Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herb vs. modern vitamins: which boosts heart health?

NCT ID NCT07206901

Disease control Sponsor: Maharishi International University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested an Ayurvedic herbal supplement called Maharishi Amrit Kalash (MAK) against vitamins C+E and a placebo in 143 Black adults aged 55+ with heart disease or high risk. The goal was to see if MAK improves blood vessel function, measured by how well arteries widen with increased blood flow. Results could suggest whether this herbal compound supports heart health better than vitamins or placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Maharishi Amrit Kalash (Ayurvedic herbal supplement)
What this could lead to
If it works, this could point toward a natural supplement that improves blood vessel health in people at high risk for heart disease.
What could go wrong
This is a small, completed trial with no phase designation, so results may not be conclusive. The supplement is not a proven treatment and should not replace standard heart medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

143 people

The number who actually took part.

Started

Oct 2002

Finished

Oct 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ethnicity: African American, self-identified * Age: 55 years and older * Medically documented coronary artery disease (CAD/CHD): defined by previous myocardial infarction OR revascularization procedure-coronary artery bypass grafting (CABG), or percutaneous transluminal coronary angioplasty (PCTA), OR coronary angiography with at least one coronary artery with \> 50% stenosis. * In the absence of documented CAD/CHD above, then at least two risk factor points on the Framingham/ATPIII risk factor scoring assessment. * Signed informed consent * Permission of Participant's primary physician (if feasible) Exclusion Criteria: * Myocardial infarction, unstable angina, coronary artery by-pass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), or stroke within preceding three months. * Carotid artery endarterectomy. * Arrhythmia atrial fibrillation, second or third degree AV block. * Congestive heart failure-Class III or IV or ejection fraction less than 30 percent. * Clinically significant valvular heart disease. * Clinically significant hepatic or renal failure. * Major psychiatric disorders, current alcohol/dependency disorder, or other drug abuse dependency disorder. * Non-cardiac life threatening illness. * Participating in a formal stress management program. * Plans to move out of the study area or travel extensively. * Unwillingness to accept randomization into any study group.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • College of Integrative Medicine

    Fairfield, Iowa, 52556, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.